2022 Annual Results
Analyst Presentation
Stuart Quin (CEO), Richard Jones (CFO) and Marc O'Brien (CIO)
4 April 2022
medica.co.uk
Document classification: Medica Restricted
Agenda
1. FY 2021 highlights
2. Financial review
3. Strategy update & focus on continued growth
a. 2021 progress
b. Organic growth opportunities & M&A
i. UK
ii. Ireland
iii. US
4. FutureTech Programme update
5. Summary and Outlook
6. Appendix
a. Detailed financials
b. ESG framework
Document classification:
Highlights
• Strong recovery in financial performance with revenues up 68% YoY and 33% vs 2019 and operating profits increasing 141% YoY and 7% compared to 2019, the last pre-Covid year.
• Strong performance from the two acquisitions in Ireland and the US
• Diversification of service offering and revenue
• Delivery of first phase of FutureTech: rollout of Sectra PACS in February ahead of time and budget
• Strong growth in NightHawk in UK with significant renewal of existing contracts together with net new contract wins
300+ | 750+ | 175+ | 1.2m+ |
Employees | Current network of | Clients | Exams and |
worldwide | specialist doctors | worldwide | Reports in |
and radiographers | 2021 | ||
worldwide | |||
medicagroupplc.com | Document classification: |
Document classification: Medica Restricted
Financial Highlights
2018 2019 2020 2021
2018 2019 2020 2021
2018 2019 2020 2021
£61.9m
Revenue
£31.4m
Gross Profit
2018 2019 2020 2021
2018 2019 2020 2021
£12.1m
Underlying operating profit*
7.83p
Underlying earnings per share**
50.7%
Gross Profit Margin
*Underlying operating profit is a non-IFRS measure and is calculated as operating profit before exceptional items and one-off costs relating to the Ireland acquisition and associated extension to the debt facility, share based payments, intangible amortisation in respect of acquired assets.
** Underlying earnings per share is a non-IFRS measure and is calculated based underlying operating profits less financing costs and taxation.
medicagroupplc.com
Document classification:
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Medica Group plc published this content on 05 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 April 2022 09:37:07 UTC.